In a phase 2 clinical trial involving 364 patients with mild dyslipidemia (TULIP), the prescription of obicetrapib at doses ranging from 1 to 10 mg for 12 weeks, both alone and in combination with moderate-intensity statins, showed favorable outcomes in ApoB concentrations. The gene discussed is APOB; the disease is metabolic syndrome.